Title alternative:
|
[More hereditary intestinal cancer can be detected if patients with colorectal carcinoma that are selected by the pathologist are examined for microsatellite instability]
|
Subject:
|
EBP 2: Effective Hospital Care IGMD 2: Molecular gastro-enterology and hepatology IGMD 3: Genomic disorders and inherited multi-system disorders NCEBP 1: Molecular epidemiology NCEBP 2: Evaluation of complex medical interventions NCMLS 2: Immune Regulation NCMLS 6: Genetics and epigenetic pathways of disease ONCOL 1: Hereditary cancer and cancer-related syndromes ONCOL 2: Age-related aspects of cancer ONCOL 3: Translational research ONCOL 4: Quality of Care ONCOL 5: Aetiology, screening and detection UMCN 1.2: Molecular diagnosis, prognosis and monitoring |
Organization:
|
Human Genetics Health Evidence Gastroenterology Surgery Pathology |
Former Organization:
|
Epidemiology, Biostatistics & HTA
|
Journal title:
|
Nederlands Tijdschrift voor Geneeskunde
|
Abstract:
|
OBJECTIVE: To determine whether an investigation of microsatellite instability (MSI) in patients with colorectal carcinoma that have been selected by the pathologist could increase the number of detected families with hereditary non-polyposis colorectal carcinoma (HNPCC). DESIGN: Prospective inventory. METHOD: Pathologists selected patients with a newly diagnosed colorectal carcinoma for MSI analysis of their tumour tissue if they met one of the following four criteria: (a) colorectal carcinoma diagnosed below 50 years of age; (b) a second colorectal carcinoma; (c) a combination of colorectal carcinoma and another HNPCC-related cancer; (d) colorectal adenoma with high-grade dysplasia diagnosed below 40 years of age. Patients with a positive MSI-test were referred to a clinical geneticist. The new strategy was introduced and explored in 5 hospitals for a period of to months. RESULTS: The new strategy was adopted and implemented successfully by pathologists and surgeons and accepted with satisfaction by the patients. Of the 55 patients included, 10 had a positive MSI-test. In 8/10 patients, DNA-mutation analysis was started by the clinical geneticist and 3 germline mutations in the MSH2-gene were detected. In 2 of 3 families with a pathogenic mutation, the family history alone did not fulfil the clinical criteria for HNPCC. CONCLUSION: Selection by the pathologist for MSI investigation was feasible in daily practice and identified more HNPCC patients than selection based on family history alone.
|